Big Money Sentiment increased to 2 in 2018 Q4. It has change of 0.59, from 2018Q3’s 1.41. The ratio improved due to Cytokinetics, Incorporated positioning: 5 sold and 29 reduced. 24 funds amassed holdings and 44 increased holdings. Investors holded 38.16 million in 2018Q3 but now own 38.60 million shares or 1.14% more.
Great Point Ptnrs Limited Liability Com owns 3.17 million shs. Texas Permanent School Fund has invested 0% of its capital in Cytokinetics, Incorporated (NASDAQ:CYTK). Prudential Inc holds 0% or 85,250 shs. California Public Employees Retirement reported 0% stake. Wasatch Advsrs Inc stated it has 0.21% in Cytokinetics, Incorporated (NASDAQ:CYTK). Moreover, Principal Gru has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 444,178 shs. Dimensional Fund L P invested in 193,871 shs. Hall Laurie J Trustee stated it has 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Arizona State Retirement System reported 84,254 shs. D E Shaw Incorporated owns 187,083 shs or 0% of their US capital. 47,878 are owned by Sector Pension Inv Board. Renaissance Ltd Liability Co has invested 0% in Cytokinetics, Incorporated (NASDAQ:CYTK). Hightower Advisors Lc stated it has 0% of its capital in Cytokinetics, Incorporated (NASDAQ:CYTK). Sectoral Asset Mngmt owns 15,582 shs. Jpmorgan Chase And Com stated it has 11,744 shs.
Cytokinetics, Incorporated had 7 insider sales and 0 buys since November 1, 2018. This’s net activity of $129,841. On Thursday, November 1 Malik Fady Ibraham had sold 1,500 shs worth $10,020.
Earnings report for Cytokinetics, Incorporated (NASDAQ:CYTK) is expected on April, 25., as reported by Faxor. Analysts expect change of 10.71 % or $0.06 from previous year’s $-0.56 EPS compared to current’s $-0.50 EPS. After $-0.48 EPS was revealed last quarter, analysts now see negative EPS growth of 4.17 % for Cytokinetics, Incorporated. The stock decreased 2.77% or $0.24 during the last trading session, hitting $8.41.Currently Cytokinetics, Incorporated is downtrending after 12.86% change in last April 8, 2018. CYTK has also 120,420 shares volume. CYTK underperformed the S&P500 by 17.23%.
Cytokinetics, Incorporated (NASDAQ:CYTK) Ratings Coverage
A total of 3 analysts rate Cytokinetics Inc (NASDAQ:CYTK) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CYTK) has 6 ratings reports on Apr 8, 2019 according to StockzIntelligence. In Wednesday, March 20 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, February 21 the stock has “Buy” rating by Cantor Fitzgerald. On Friday, February 22 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, March 19 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, February 20 Piper Jaffray maintained the shares of CYTK in report with “Buy” rating. The company rating was maintained by Piper Jaffray on Wednesday, March 20.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.The firm is valued at $465.69 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.Last it reported negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.
For more Cytokinetics, Incorporated (NASDAQ:CYTK) news brought out recently go to: Benzinga.com, Nasdaq.com, Benzinga.com, Benzinga.com or Globenewswire.com. The titles are as follows: “52 Biggest Movers From Yesterday – Benzinga” brought out on March 21, 2019, “Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19 – Nasdaq” on March 18, 2019, “41 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with a publish date: March 20, 2019, “60 Biggest Movers From Yesterday – Benzinga” and the last “Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results – GlobeNewswire” with publication date: November 01, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.